Canopus Biopharma In (CBIA) 0.1000 $CBIA
Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China
PR Newswire - Tue Jul 01, 9:00AM CDT
Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM).
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Latest Rhinovirus Infection Pipeline Review
M2 - Tue Jan 28, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5q9nz/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H2 2013" report to their offering. 'Rhinovirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Scope - A snapshot of the global therapeutic scenario for Rhinovirus Infection. - A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Canopus BioPharma Incorporated - Cocrystal Discovery, Inc. - Sealife PHARMA GMBH - Polyrizon Ltd. Drug Profiles - SLP-0904 - OBR-5-340 - CB-1600 - Drug For Rhinovirus Infection - SLP-1001 - Human Rhinovirus Program - PL-402 - Human Rhinovirus Inhibitors - Rhinovirus Program - KR-22809 - Amiloride Derivatives For more information visit http://www.researchandmarkets.com/research/m5q9nz/rhinovirus
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Dental Caries - Pipeline Review, H2 2013
M2 - Wed Dec 11, 4:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/rw8xf3/dental_caries) has announced the addition of the "Dental Caries - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Dental Caries, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Caries. Dental Caries - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dental Caries. - A review of the Dental Caries products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Caries pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Dental Caries. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Caries pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Aphios Corporation - Oragenics - C3 Jian - Canopus BioPharma Incorporated - Ensoltek For more information visit http://www.researchandmarkets.com/research/rw...tal_caries About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Oral Mucositis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wgg6sd/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2013" report to their offering. 'Oral Mucositis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. Scope - A snapshot of the global therapeutic scenario for Oral Mucositis. - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Oral Mucositis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Oral Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Daewoong Pharmaceutical Co., Ltd. Soligenix, Inc. BioAlliance Pharma SA Sucampo Pharmaceuticals, Inc. ActogeniX NV Alder Biopharmaceuticals Inc. Promedior, Inc. ProCertus BioPharm Inc. GliaMed, Inc. Avaxia Biologics, Inc. Canopus BioPharma Incorporated Nephrx Corporation Tosk, Inc. Laila Pharmaceuticals Pvt. Ltd. Applied Protein Sciences, LLC For more information visit http://www.researchandmarkets.com/research/wg..._mucositis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod
Mucositis - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z2zdt/mucositis) has announced the addition of the "Mucositis - Pipeline Review, H1 2013" report to their offering. "Mucositis - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identify
H3N2 Infection - Pipeline Review, H1 2013 Featuring 7 Key Companies and 9 Drug Profiles
M2 - Mon Apr 29, 4:21AM CDT
Research and Markets has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2013" report to their offering. 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. Scope - A snapshot of the global therapeutic scenario for H3N2 Infection. - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the H3N2 Infection pipeline on the basis of route of
Canopus BioPharma Incorporated - Product Pipeline Review - 2012
M2 - Mon Feb 18, 3:33AM CST
Summary
Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China
PR Newswire - Tue Jul 01, 9:00AM CDT
Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM).
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Latest Rhinovirus Infection Pipeline Review
M2 - Tue Jan 28, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5q9nz/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H2 2013" report to their offering. 'Rhinovirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Scope - A snapshot of the global therapeutic scenario for Rhinovirus Infection. - A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Canopus BioPharma Incorporated - Cocrystal Discovery, Inc. - Sealife PHARMA GMBH - Polyrizon Ltd. Drug Profiles - SLP-0904 - OBR-5-340 - CB-1600 - Drug For Rhinovirus Infection - SLP-1001 - Human Rhinovirus Program - PL-402 - Human Rhinovirus Inhibitors - Rhinovirus Program - KR-22809 - Amiloride Derivatives For more information visit http://www.researchandmarkets.com/research/m5q9nz/rhinovirus
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
Dental Caries - Pipeline Review, H2 2013
M2 - Wed Dec 11, 4:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/rw8xf3/dental_caries) has announced the addition of the "Dental Caries - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Dental Caries, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Caries. Dental Caries - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dental Caries. - A review of the Dental Caries products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Caries pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Dental Caries. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Caries pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Aphios Corporation - Oragenics - C3 Jian - Canopus BioPharma Incorporated - Ensoltek For more information visit http://www.researchandmarkets.com/research/rw...tal_caries About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Oral Mucositis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wgg6sd/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2013" report to their offering. 'Oral Mucositis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. Scope - A snapshot of the global therapeutic scenario for Oral Mucositis. - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Oral Mucositis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Oral Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Daewoong Pharmaceutical Co., Ltd. Soligenix, Inc. BioAlliance Pharma SA Sucampo Pharmaceuticals, Inc. ActogeniX NV Alder Biopharmaceuticals Inc. Promedior, Inc. ProCertus BioPharm Inc. GliaMed, Inc. Avaxia Biologics, Inc. Canopus BioPharma Incorporated Nephrx Corporation Tosk, Inc. Laila Pharmaceuticals Pvt. Ltd. Applied Protein Sciences, LLC For more information visit http://www.researchandmarkets.com/research/wg..._mucositis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod
Mucositis - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z2zdt/mucositis) has announced the addition of the "Mucositis - Pipeline Review, H1 2013" report to their offering. "Mucositis - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identify
H3N2 Infection - Pipeline Review, H1 2013 Featuring 7 Key Companies and 9 Drug Profiles
M2 - Mon Apr 29, 4:21AM CDT
Research and Markets has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2013" report to their offering. 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. Scope - A snapshot of the global therapeutic scenario for H3N2 Infection. - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the H3N2 Infection pipeline on the basis of route of
Canopus BioPharma Incorporated - Product Pipeline Review - 2012
M2 - Mon Feb 18, 3:33AM CST
Summary
